Telix Pharmaceuticals (TLX) Non-Current Assets (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Non-Current Assets for 3 consecutive years, with $833.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 113.24% to $833.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $833.7 million through Dec 2025, up 113.24% year-over-year, with the annual reading at $833.7 million for FY2025, 125.17% up from the prior year.
  • Non-Current Assets for Q4 2025 was $833.7 million at Telix Pharmaceuticals, up from $391.0 million in the prior quarter.
  • The five-year high for Non-Current Assets was $833.7 million in Q4 2025, with the low at $112.9 million in Q4 2023.
  • Average Non-Current Assets over 3 years is $445.9 million, with a median of $391.0 million recorded in 2024.
  • The sharpest move saw Non-Current Assets skyrocketed 246.25% in 2024, then skyrocketed 113.24% in 2025.
  • Over 3 years, Non-Current Assets stood at $112.9 million in 2023, then surged by 246.25% to $391.0 million in 2024, then surged by 113.24% to $833.7 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $833.7 million, $391.0 million, and $112.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.